You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Why Should We Test for Lipoprotein(a)? The Experts Discuss

  • Authors: Kausik K. Ray, MD, MPhil, FRCP; Robert A. Hegele, MD, FRCPC, FACP; Borge Nordestgaard, MD; Eric S. Stroes, MD
  • CPD Released: 10/12/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/12/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of cardiologists and primary care physicians.

The goal of this activity is to educate on lipoprotein(a) [Lp(a)] and how global/holistic risk management is important for cardiovascular (CV) risk management despite the present lack of availability of Lp(a)-specific therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • CV risk assessment and value of Lp(a)
    • The contribution of Lp(a) to a higher-CV-risk profile
  • Have greater competence related to
    • Managing a patient whose Lp(a) level is raised by aggressive and urgent treatment of CV risk factors


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Kausik K. Ray, MD, MPhil, FRCP

    Professor of Public Health
    Honorary Consultant Cardiologist
    Imperial Centre for Cardiovascular Disease Prevention
    Department of Primary Care and Public Health
    Imperial College London
    London, United Kingdom

    Disclosures

    Disclosure: Kausik K. Ray, MD, MPhil, FRCP, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Eli Lilly; Esperion; Kowa; New Amsterdam; Novartis; Resverlogix; Silence Therapeutics
    Speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lupin; Novartis; Novo Nordisk; Pfizer; Sanofi
    Grants for clinical research from: Amgen; Daiichi Sankyo; Imperial College London; Regeneron
    Stocks, stock options, or bonds from: Cargene Therapeutics; Pemi31 Therapeutics

  • Robert A. Hegele, MD, FRCPC, FACP

    Jacob J. Wolfe Distinguished Medical Research Chair
    Martha Blackburn Chair in Cardiovascular Research
    Distinguished University Professor of Medicine and Biochemistry
    University of Western Ontario
    London, Ontario, Canada

    Disclosures

    Disclosure: Robert A. Hegele, MD, FRCPC, FACP, has the following relevant financial relationships:
    Advisor or consultant for: Acasti; Akcea-Ionis; Amgen; Arrowhead; HLS Therapeutics; Novartis; Pfizer; Regeneron; Sanofi
    Speaker or a member of a speakers bureau for: Amgen; HLS Therapeutics; Pfizer; Novartis

  • Borge Nordestgaard, MD

    Professor
    University of Copenhagen
    Chief Physician
    Department Clinical Biochemistry
    Herlev and Gentofte Hospital
    Copenhagen University Hospital
    Copenhagen, Denmark

    Disclosures

    Disclosure: Borge Nordestgaard, MD, has the following relevant financial relationships:
    Advisor or consultant for: Akcea; Amarin; Amgen; AstraZeneca; Denka; Esperion; Kowa; Novartis; Novo Nordisk; Regeneron; Sanofi; Silence Therapeutics
    Speaker or a member of a speakers bureau for: Denka; Kowa; Novartis

  • Eric S. Stroes, MD

    Professor
    Department of Vascular Medicine
    Academic Medical Center
    Amsterdam, The Netherlands

    Disclosures

    Disclosure: Eric S. Stroes, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; AstraZeneca; Esperion; Ionis-Akcea; Novo Nordisk; Regeneron; Sanofi
    Speaker or a member of a speakers bureau for: Medcon Europe BV
    Grants for clinical research from: Dutch Heart Foundation, European Union

Editor

  • Ozerk Akgun, MD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Ozerk Akgun, MD, has disclosed no relevant financial relationships.

Content Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Why Should We Test for Lipoprotein(a)? The Experts Discuss

Authors: Kausik K. Ray, MD, MPhil, FRCP; Robert A. Hegele, MD, FRCPC, FACP; Borge Nordestgaard, MD; Eric S. Stroes, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 10/12/2021

Valid for credit through: 10/12/2022

processing....

Educational Impact Challenge

The goal of this activity is to educate on lipoprotein(a) [Lp(a)] and how global/holistic risk management is important for cardiovascular (CV) risk management despite the present lack of availability of Lp(a)-specific therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.